Non-pharmacological strategies to enhance adherence and continuity of care in schizophrenia

Adherence to Antipsychotics in Schizophrenia

Volumn , Issue , 2014, Pages 99-137

  Vita, Antonio ^a   Barlati, Stefano ^b   Sacchetti, Emilio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adherence; Cognitive behavioral therapy; Environmental supports; Psychoeducation; Schizophrenia

Indexed keywords

EID: 84937769996     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-2679-7_3     Document Type: Chapter

References (157)

1. Clayton CD, Veach J, Macfadden W et al (2010) Assessment of clinician awareness of nonadherenceusing a new structured rating scale. Psychiatr Pract 16(3):164–169
2. Tandon R, Nasrallah HA, Keshavan MS (2010) Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res 122(1-3):1–23
3. Goff DC, Hill M, Freudenreich O (2010) Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 71(Suppl 2):20–26
4. Ascher-Svanum H, Faries DE, Zhu B et al (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67(3):453–460
5. Valenstein M, Copeland LA, Blow FC et al (2002) Pharmacy data identify poorly adherentpatients with schizophrenia at increased risk for admission. Med Care 40:630–639
6. Gilmer TP, Dolder CR, Lacro JP et al (2004) Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161:692–699
7. Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21(3):419–429
8. Dolder CR, Lacro JP, Leckband S et al (2003) Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 23:389–399
9. Julius RJ, Novitsky MA Jr, Dubin WR (2009) Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 15(1):34–44
10. Velligan DI, Weiden PJ, Sajatovic M et al (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. expert consensus anel on adherence problems in serious and persistent mental illness. J Clin Psychiatry 70 (Suppl 4):1–46
11. Hardeman SM, Harding RK, Narasimhan M (2010) Simplifying adherence in chizophrenia. Psychiatr Serv 61(4):405–408
12. McCann TV, Boardman G, Clark E, et al (2008) Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs 15(8):622–629
13. Scott J (1999) Cognitive and behavioural approaches to medication adherence. Adv Psych Treat 5:338–347
14. Saykin AJ, Gur RC, Gur RE et al (1991) Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48:618–624
15. Liddle PF (1987) Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psych Med 17:49–57
16. Heaton R, Paulsen JS, McAdams LA et al (1994) Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Arch Gen Psychiatry 51:469–476
17. Barkhof E, Meijer CJ, de Sonneville LM et al (2012) Interventions to improve adherence to antipsychotic medication in patients with schizophrenia—a review of the past decade. Eur Psychiatry 27(1):9–18
18. Weiden PJ, Shaw E, Mann J (1986) Causes of neuroleptic noncompliance. Psychiatr Ann 16:571–575
19. Rettenbacher MA, Hofer A, Eder U et al (2004) Compliance in schizophrenia: psychopathology, side effects, and patients’ attitudes toward the illness and medication. J Clin Psychiatry 65(9):1211–1218
20. Lacro J (2006) Optimizing adherence to treatment in patients with schizophrenia. Behav Healthc 26(8):38–42
21. Kern RS, Glynn SM, Horan WP et al (2009) Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull 35(2):347–361
22. Patterson TL, Leeuwenkamp OR (2008) Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res 100(1–3):108–119. Tacchi MJ, Scott J (2005) Improving adherence in schizophrenia and bipolar disorders. Wiley, Chichester
23. WHO (eds) (2003) Adherence to long-term therapies: evidence for action. WHO, Geneva
24. Zygmunt A, Olfson M, Boyer CA et al (2002) Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 159(10):1653–1664
25. Kane JM (2011) Improving treatment adherence in patients with schizophrenia. J Clin Psychiatry 72(9):e28
26. Kane JM (2006) Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 67(Suppl 5):9–14
27. Velligan DI, Diamond PM, Mintz J et al (2008) The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 34(3):483–493
28. Mari JJ, Streiner DL (1994) An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. Psychol Med 24(3):565–578
29. Pitschel-Walz G, Leucht S, Bäuml J et al (2001) The effect of family interventions on relapse and rehospitalization in schizophrenia—a meta-analysis. Schizophr Bull 27(1):73–92
30. Pilling S, Bebbington P, Kuipers E et al (2002) Psychological treatments in schizophrenia: I. meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 32(5):763–782
31. Girón M, Fernández-Yañez A, Mañá-Alvarenga S et al (2010) Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study. Psychol Med 40(1):73–84
32. Pharoah F, Mari J, Rathbone J et al (2006) Family intervention for schizophrenia. Cochrane Database Syst Rev 18(4):CD000088
33. Lincoln TM, Wilhelm K, Nestoriuc Y (2007) Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 96(1–3):232–245
34. Seltzer A, Roncari I, Garfinkel P (1980) Effect of patient education on medication compliance. Can J Psychiatry 25(8):638–645
35. Brown CS, Wright RG, Christensen DB (1987) Association between type of medication instruction and patients’ knowledge, side effects, and compliance. Hosp Community Psychiatry 38(1):55–60
36. Goldman CR, Quinn FL (1988) Effects of a patient education program in the treatment of schizophrenia. Hosp Community Psychiatry 39(3):282–686
37. Streicker S, Amdur M, Dincin J (1986) Educating patients about psychiatric medications: failure to enhance compliance. Psychosoc Rehabil J 9:15–28
38. Maurel M, Drai D, Kaladjian A et al (2010) A randomized controlled study on the impact of pharmacoeducation on a French patient population with schizophrenic and schizoaffective disorders. Can J Psychiatry 55(5):329–337
39. Xia J, Merinder LB, Belgamwar MR (2011) Psychoeducation for schizophrenia. Cochrane Database Syst Rev 15(6):CD002831
40. Dixon L, McFarlane WR, Lefley H et al (2001) Evidence-based practices for services to families of people with psychiatric disabilities. Psychiatr Serv 52(7):903–910
41. Xiang M, Ran M, Li S (1994) A controlled evaluation of psychoeducational family intervention in a rural Chinese community. Br J Psychiatry 165(4):544–548
42. Ran MS, Xiang MZ, Chan CL et al (2003) Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia–a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 38(2):69–75
43. Chan SW, Yip B, Tso S et al (2009) Evaluation of a psychoeducation program for Chinese clients with schizophrenia and their family caregivers. Patient Educ Couns 75(1):67–76
44. Pitschel-Walz G, Bäuml J, Bender W et al (2006) Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich psychosis information project study. J Clin Psychiatry 67(3):443–452
45. Bäuml J, Pitschel-Walz G, Volz A et al (2007) Psychoeducation in schizophrenia: 7-year follow-up concerning rehospitalization and days in hospital in the Munich psychosis information project study. J Clin Psychiatry 68(6):854–861
46. Kopelowicz A, Zarate R, Wallace CJ et al (2012) The ability of multifamily groups to improve treatment adherence in Mexican Americans with schizophrenia. Arch Gen Psychiatry 69(3):265–273
47. Leff J, Berkowitz R, Shavit N et al (1990) A trial of family therapy versus a relatives’ group for schizophrenia two-year follow-up. Br J Psychiatry 157:571–577
48. Zhang M, Wang M, Li J et al (1994) Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou Jiangsu. Br JPsychiatry 165(Suppl 24):96–102
49. Haas GL, Glick ID, Clarkin JF et al (1988) Inpatient family intervention: a randomized clinical trial. II. Results at hospital discharge. Arch Gen Psychiatry 45(3):217–224
50. Herz MI (1996) Psychosocial treatment. Psychiatr Ann 26:531–535
51. Pharoah F, Mari J, Rathbone J et al (2010) Family intervention for schizophrenia. Cochrane Database Syst Rev 8(12):CD000088
52. Turkington D, Kingdon D, Weiden PJ (2006) Cognitive behavior therapy for schizophrenia. Am J Psychiatry 163(3):365–373
53. Tai S, Turkington D (2009) The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments. Schizophr Bull 35(5):865–873
54. NICE (2009) Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Institute of Clinical Excellence, London
55. Dixon LB, Dickerson F, Bellack AS et al (2010) The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 36(1):48–70
56. Durham RC, Chambers JA, Power KG et al (2005) Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technol Assess 9(42):1–174
57. Garety PA, Fowler DG, Freeman D et al (2008) Cognitive–behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomized controlled trial. Br J Psychiatry 192(6):412–423
58. Eckman TA, Liberman RP, Phipps CC et al (1990) Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol 10(1):33–38
59. Boczkowski JA, Zeichner A, DeSanto NJ (1985) Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report. Consult Clin Psychol 53(5):666–671
60. Cramer JA, Rosenheck R (1999) Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 187(1):53–55
61. Razali MS, Hasanach CL, Khan A et al (2000) Psychosocial interventions for schizophrenia. J Ment Health 9:283–289
62. Jones C, Hacker D, Cormac I et al (2012) Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 18(4):CD008712
63. Lecompte D, Pelc I (1996) A cognitive-behavioural program to improve compliance with medication in patients with schizophrenia. Int J Ment Health 25:51–56
64. Rollnick S, Miller WR (1995) What is motivational interviewing? Behavioural and cognitive psychotherapy. Cognit Psychother 23:325–334
65. Hayward P, Chan N, Kemp R et al (1995) Medication selfmanagement: a preliminary report on an intervention to improve medication compliance. J Ment Health 4:511–517
66. Kemp R, David A (1996) Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 169(4):444–450
67. Kemp R, Hayward P, Applewhaite G et al (1996) Compliance therapy in psychotic patients: randomised controlled trial. BMJ 312(10):345–349
68. Kemp R, Hayward P, David A (1997) Compliance therapy manual. The Maudsley, London
69. Kemp R, Kirov G, Everitt B et al (1998) Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 172:413–419
70. Gray R, Robson D, Bressington D (2002) Medication management for people with a diagnosis of schizophrenia. Nurs Times 98(47):38–40
71. O’Donnell C, Donohoe G, Sharkey L et al (2003) Compliance therapy: a randomized controlled trial in schizophrenia. BMJ 327(7419):834
72. Byerly MJ, Fisher R, Carmody T et al (2005) A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 66(8):997–1001
73. McIntosh AM, Conlon L, Lawrie SM (2006) Compliance therapy for schizophrenia. Cochrane Database Syst Rev 19(3):CD003442
74. Gray R, Leese M, Bindman J et al (2006) Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 189:508–514
75. Maneesakorn S, Robson D, Gournay K et al (2007) An RCT of adherence therapy for people with schizophrenia in Chiang Mai Thailand. J Clin Nurs 16(7):1302–1312
76. Anderson KH, Ford S, Robson D et al (2010) An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. Int J Ment Health Nurs 19(5):340–349
77. Uzenoff SR, Perkins DO, Hamer RM et al (2008) A preliminary trial of adherence-copingeducation (ACE) therapy for early psychosis. J Nerv Ment Dis 196(7):572–575
78. Staring AB, Van der Gaag M, Koopmans GT et al (2010) Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 197(6):448–455
79. Becker MH, Maiman LA (1975) Sociobehavioral determinants of compliance with healthand medical care recommendations. Med Care 13:10–24
80. Becker MH, Maiman LA, Kirscht JP et al (1977) The health belief model and prediction of dietary compliance: a field experiment. J Health Soc Behav 18(4):348–366
81. Becker MH (1985) Patient adherence to prescribed therapies. Med Care 23(5):539–555
82. Rosenstock IM (1974) Historical origins of the health belief model. Health Educ Monogr 2:409–419
83. Marder SR, May PR (1986) Benefits and limitations of neuroleptics—and other forms of treatment—in schizophrenia. Am J Psychother 40(3):357–369
84. Albus M (1995) The problem of drug compliance in schizophrenic patients. Psychiatr Prax 22(6):221–222
85. Razali MS, Yahya H (1995) Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand 91(5):331–335
86. Johnson DA, Freeman H (1973) Drug defaulting by patients on long-acting phenothiazines.Psychol Med 3(1):115–119
87. Johnson DA (1977) Treatment of chronic schizophrenia. Drugs 14(4):291–299
88. Soskis DA (1978) Schizophrenic and medical inpatients as informed drug consumers. Arch Gen Psychiatry 35(5):645–647
89. Marder SR, Mebane A, Chien CP et al (1983) A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 140(4):470–472
90. Marder SR, Swann E, Winslade WJ et al (1984) A study of medication refusal by involuntary psychiatric patients. Hosp Community Psychiatry 35(7):724–726
91. Horne R, Weinman J (1998) Predicting treatment adherence: an overview of theoretical models. In: Myers LB, Midence K (eds) Adherence to treatment in medical conditions. Harwood Academic Press, Amsterdam, pp 25–50
92. Weinstein ND (1988) The precaution adoption process. Health Psychol 7:355–386
93. Perkins DO (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63(12):1121–1128
94. Lacro JP, Dunn LB, Dolder CR et al (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63(10):892–909
95. Garavan J, Browne S, Gervin M et al (1998) Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 39(4):215–219
96. Velligan DI, Weiden PJ (2006) Interventions to improve adherence to antipsychotic medication. Psychiatric Times 23(9):1–2
97. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23(4):637–651
98. Frank AF, Gunderson JG (1990) The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 47(3):228–236
99. Weiss KA, Smith TE, Hull JW et al (2002) Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 28(2):341–349
100. Fleischhacker WW, Meise U, Günther V et al (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 382:11–15
101. Budd RJ, Hughes IC, Smith JA (1996) Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 35(3):393–397
102. Champion VL (1984) Instrument development for health belief model constructs. ANS AdvNurs Sci 6(3):73–85
103. Pan PC, Tantam D (1989) Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 79(6):564–570
104. Adams J, Scott J (2000) Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 101(2):119–124
105. Robinson DG, Woerner MG, Alvir JM et al (2002) Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 57:209–219
106. Grunebaum MF, Weiden PJ, Olfson M (2001) Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 62(5):394–399
107. Oehl M, Hummer M, Fleischhacker WW (2000) Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 102(407):83–86
108. Babiker IE (1986) Noncompliance in schizophrenia. Psychiatr Dev 4(4):329–337
109. Bebbington PE (1995) The content and context of compliance. Int Clin Psychopharmacol 9(Suppl 5):41–50
110. Kinderman P, Setzu E, Lobban F et al (2006) Illness beliefs in schizophrenia. Soc Sci Med 63(7):1900–1911
111. Velligan DI, Mueller J, Wang M et al (2006) Use of environmental supports among patients with schizophrenia. Psychiatr Serv 57(2):219–224
112. Velligan DI, Prihoda TJ, Ritch JL et al (2002) A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients. Schizophr Bull 28(2):283–292
113. Velligan DI, Bow-Thomas CC (2000) Two case studies of cognitive adaptation training for outpatients with schizophrenia. Psychiatr Serv 51(1):25–29
114. Velligan DI, Bow-Thomas CC, Huntzinger C et al (2000) Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 157(8):1317–1323
115. Velligan DI, Mueller J, Wang M et al (2006) Use of environmental supports among patients with schizophrenia. Psychiatr Serv 57(2):219–224
116. Velligan DI, Diamond P, Mueller J et al (2009) The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia. Psychiatry Res 168(2):94–101
117. Valenstein M, Kavanagh J, Lee T et al (2011) Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull 37(4):727–736
118. Pijnenborg GH, Withaar FK, Brouwer WH et al (2010) The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. Br J Clin Psychol 49(Pt 2):259–274
119. Salzer MS, Tunner T, Charney NJ (2004) A low-cost, telephone intervention to enhance schizophrenia treatment: a demonstration study. Schizophr Res 66(1):75–76
120. Beebe LH, Smith K, Crye C et al (2008) Telenursing intervention increases psychiatric medication adherence in schizophrenia outpatients. J Am Psychiatr Nurses Assoc 14(3):217–224
121. Spaniel F, Vohlídka P, Hrdlicka J et al (2008) ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res 98(1–3):312–317
122. Kurtz MM, Baker E, Pearlson GD et al (2007) A virtual reality apartment as a measure of medication management skills in patients with schizophrenia: a pilot study. Schizophr Bull 33(5):1162–1170
123. Janssen B, Ludwig S, Eustermann H et al (2010) Improving outpatient treatment in schizophrenia: effects of computerized guideline implementation—results of a multicenterstudy within the German research network on schizophrenia. Eur Arch Psychiatry Clin Neurosci 260(1):51–57
124. Marshall M, Lockwood A (2000) Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2:CD001089
125. Marshall M, Gray A, Lockwood A et al (2000) Case management for people with severe mental disorders. Cochrane Database Syst Rev 2:CD000050
126. Bond GR, McGrew JH, Fekete DM (1995) Assertive outreach for frequent users of psychiatric hospitals: a meta-analysis. J Ment Health Adm 22(1):4–16
127. Coldwell CM, Bender WS (2007) The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. Am J Psychiatry 164(3):393–399
128. Nelson G, Aubry T, Lafrance A (2007) A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. Am J Orthopsychiatry 77(3):350–361
129. Burns T, Catty J, Dash M et al (2007) Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ:335(7615):336
130. Stein LI, Test MA (1980) Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 37(4):392–397
131. Ford R, Beadsmore A, Ryan P et al (1995) Providing the safety net: case management for people with serious mental illness. J Ment Health 1:91–97
132. Bond GR, Miller LD, Krumwied RD et al (1988) Assertive case management in three CMHCs: a controlled study. Hosp Community Psychiatry 39(4):411–418
133. Solomon P, Draine J (1995) The efficacy of a consumer case management team: 2-year outcomes of a randomized trial. J Ment Health Adm 22(2):135–146
134. Dixon L, Weiden P, Torres M et al (1997) Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiatry 154(9):1302–1304
135. McEvoy JP, Scheifler PL, Frances A et al (1999) The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 60(Suppl 11):3–80
136. Gray R, Wykes T, Gournay K (2003) The effect of medication management training on community mental health nurse’s clinical skills. Int J Nurs Stud 40(2):163–169
137. Gray R, Wykes T, Edmonds M et al (2004) Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomized controlled trial. Br J Psychiatry 185:157–162
138. Hudson TJ, Owen RR, Thrush CR et al (2008) Guideline implementation and patienttailoring strategies to improve medication adherence for schizophrenia. J Clin Psychiatry 69(1):74–80
139. Linden M, Pyrkosch L, Hundemer HP (2008) Frequency and effects of psychosocial interventions additional to olanzapine treatment in routine care of schizophrenic patients. Soc Psychiatry Psychiatr Epidemiol 43(5):373–379
140. Guo X, Zhai J, Liu Z et al (2010) Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year study. Arch Gen Psychiatry 67(9):895–904
141. Misdrahi D, Petit M, Blanc O et al (2012) The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nord J Psychiatry 66(1):49–54
142. Deegan PE, Drake RE (2006) Shared decision making and medication management in the recovery process. Psychiatr Serv 57(11):1636–1639
143. Drake RE, Deegan PE, Rapp C (2010) The promise of shared decision making in mental health. Psychiatr Rehabil J 34(1):7–13
144. Mistler LA, Drake RE (2008) Shared decision making in antipsychotic management. J Psychiatr Pract 14(6):333–344
145. Perkins DO, Gu H, Weiden PJ et al (2008) Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 69(1):106–113
146. Kelly GR, Scott JE, Mamon J (1990) Medication compliance and health education among outpatients with chronic mental disorders. Med Care 28(12):1181–1197
147. Hogarty GE, Anderson CM, Reiss DJ et al (1991) Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) research group. Arch Gen Psychiatry 48(4):340–347
148. Guimon L, Eguiluz I, Bulbena A (1993) Group pharmacotherapy in schizophrenics: attitudinal and clinical changes. Eur J Psychiatry 7(3):147–154
149. Azrin NH, Teichner G (1998) Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients. Behav Res Ther 36(9):849–861
150. Petersen L, Jeppesen P, Thorup A et al (2005) A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 331(7517):602
151. Masand PS, Narasimhan M (2006) Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 1(1):47–56
152. Valencia M, Rascon ML, Juarez F et al (2007) A psychosocial skills training approach in Mexican out-patients with schizophrenia. Psychol Med 37(10):1393–1402
153. Morken G, Grawe RW, Widen JH (2007) Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. J Clin Psychiatry 68(4):566–571
154. Haynes RB, Ackloo E, Sahota N et al (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 16(2):CD000011
155. Beck EM, Cavelti M, Kvrgic S et al (2011) Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res 132(1):42-49
156. Kikkert MJ, Schene AH, Koeter MW et al (2006) Medication adherence in schizophrenia: exploring patients’, carers’ and professionals’ views. Schizophr Bull 32(4):786–794
157. Rüsch N, Todd AR, Bodenhausen GV et al (2009) Implicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence. Schizophr Res 112(1–3):119–122